Loading
A phase 2 trial of osimertinib and telisotuzumab vedotin in lung cancer, run by Jonsson Comprehensive Cancer Center, now recruiting.
Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer is a phase 2, interventional study registered as NCT07323641 by Jonsson Comprehensive Cancer Center, with a registry enrolment figure of 60 participants, started 2026-02-19 and due to reach its primary completion in 2027-02-01. Interventions recorded: Biopsy Procedure; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Osimertinib; Survey Administration; Telisotuzumab Vedotin. Conditions listed: Lung Non-Small Cell Carcinoma. Primary outcome: Objective response rate (ORR); Progression free survival (PFS). Lung eligibility wording from the registry: "* Cytologically or histologically confirmed non small cell lung cancer (NSCLC), which is incurable with an activating and sensitizing EGFR mutation (e". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Antibody-drug conjugate (ADC) and the tag lung-deep-dive.